An industry leader in human and veterinary vaccine adjuvants developed various immuostimulators and adjuvant systems which are used in various veterinary vaccines. 

This Company is a UK based multinational company and is a global leader in high performance ingredients and technologies that are found in some of the most successful brands in the world across a wide range of markets. The Pharma Branch is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations, we are committed to enabling the next generation of drug delivery systems. As a business, it is focused on empowering biologics drug delivery, through our vaccine adjuvant systems as well as small molecule-, protein-, and nucleic acid delivery platforms.Its comprehensive portfolio of components accelerates the production of complete vaccines including especially immuostimulators and adjuvant systems. 

A versatile immunostimulatory saponin that’s widely used as a potent veterinary adjuvant, Quil-A can work against both intra- and extra-cellular pathogens, stimulating innate and Th-mediated adaptive immune responses. This natural extract is from the bark of the Quillaja Saponaria Molina tree. It is purified and contains a concentrated and heterogeneous mixture of over 100 saponin components. It has a strong affinity for cholesterol and can combine to form cage-like immunostimulating complexes (ISCOMs). They are known to stimulate strong cellular and humoral immune responses. Quil-A is used in various veterinary vaccines, for farm animals as well as companion animals, for example, cattle, pigs, sheep, poultry, cats, and dogs.

A powerful immunostimulatory saponin that acts as a potent vaccine adjuvant, QS21 can stimulate both cell-mediated (Th1) and humoral (Th2) immune responses. QS21 is derived from the soap-bark tree (Quillaja saponaria Molina) native to South America. It is a specific fraction of our Quil-A™ saponin mixture, selected for its rich source of triterpenoid saponins, potent immunogenicity, and low reactogenicity. The popularity of saponin-based adjuvants is a testament to their unique immunological profile. QS 21 is currently utilised in commercial vaccines against shingles and malaria. It is a key component in the ongoing development of various vaccine candidates, for conditions such as melanoma, tuberculosis, and HIV/AIDS. With amphiphilic properties, QS 21 can be formulated with lipids to dramatically reduce cell lysis. In turn, this allows for strong control of potential side effects in final formulations.

Preclinical

Looking for Buyer / Collaborations on strategic projects with vaccine developers 

Erika HAN

Tel: 086-028-85335757

Email: Erika_han@eupic.cn